H.C. Wainwright analyst Yi Chen raised the firm’s price target on Regenxbio to $38 from $36 and keeps a Buy rating on the shares following the Q1 report. The firm says the company’s Duchenne muscular dystrophy pivotal trial of RGX-202 is slated to start in the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX: